| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 11.76 | 22.0% |
| Total Income | 11.76 | 22.0% |
| Expenditure | 12.63 | 16.1% |
| PBT | -0.81 | 30.8% |
| Net Profit | -0.81 | 30.8% |
| OPM | -7.35% | 5.57pp |
| NPM | -6.86% | 5.24pp |
| EPS | -0.02 | 166.7% |
KORU Medical Systems Announces Q1 2026 Results: Revenue Up 22% YoY
07 May 2026 · 7 May, 1:39 am
Summary
KORU Medical Systems announced its financial results for the first quarter ended March 31, 2026, reporting net revenues of $11.8 million, a 22% increase compared to the prior year period. Gross profit grew by 20% to $7.2 million, with a gross margin of 61.5%. The net loss improved by 31% to ($0.8) million. The company reiterated its full year 2026 net revenue guidance between $47.5 - $50.0 million, representing growth of 15% - 22%.
Key Highlights
- 1
KORU Medical Systems reported first quarter 2026 net revenues of $11.8 million, representing a 22% increase over the prior year period.
- 2
Gross profit for the first quarter of 2026 grew by 20% to $7.2 million, with a gross margin of 61.5%.
- 3
The company's net loss for the first quarter of 2026 improved by 31% to ($0.8) million.
- 4
KORU Medical's cash balance at the end of the first quarter of 2026 was $8.8 million, reflecting cash usage of approximately $0.1 million.
- 5
Domestic core revenues were $7.7 million, an increase of 11.7% over the prior year period.
- 6
International core revenues were $3.3 million, an increase of 35.2% over the prior year period.
- 7
The company reiterated its full year 2026 net revenue guidance between $47.5 - $50.0 million, representing growth of 15% - 22%.
Management Comments
Linda Tharby
We are proud to deliver a record start to 2026, with $11.8 million in revenue, representing 22% growth. Our Core business continues to outperform the underlying SCIg market, driven increased share gains in current and new accounts. Internationally, momentum remains robust as we expand into prefilled syringe markets with our patient-preferred Freedom Infusion System. With a growing recurring patient base and scalable commercial model, Koru is well positioned for further success.
Adam Kalbermatten
Equally exciting to our strength in core markets is the momentum we are building in new drug categories with our support of late-stage molecules through their regulatory pathways, including compelling oncology opportunities ahead. A strong team, a clear strategic roadmap, and an expanding platform to access new therapies and new geographies, makes me confident in our long-term strategy and the strong foundation we have built to execute.
Informational and educational content only. Not investment advice.